DaVita’s second quarter results surpassed Wall Street’s revenue and adjusted profit expectations, but the market response was notably negative. Management attributed this to a mix of operational and industry-specific challenges, including flat treatment volumes and sequential declines in revenue per treatment, primarily due to a less favorable commercial mix and reduced revenue from phosphate binders. CEO Javier Rodriguez emphasized, “Our growth is mainly performance clinical—that expands life, and therefore, you get the volume treatment,” highlighting improved patient mortality as a key factor. However, higher general and administrative expenses and only modest gains from recent industry consolidation contributed to investor caution.

Is now the time to buy DVA? Find out in our full research report (it’s free for active Edge members).

While we enjoy listening to the management’s commentary, our favorite part of earnings calls is the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.

Our Top 5 Analyst Questions From DaVita’s Q2 Earnings Call

• Andrew Mok (Barclays) pressed on why U.S. dialysis operating income was flat despite volume growth. CFO Joel Ackerman explained that higher costs per treatment and increased general and administrative expenses offset the benefit from volume gains.
• Albert Rice (UBS) asked about the financial impact of deploying expanded HD technology. CEO Javier Rodriguez and Ackerman clarified that near-term economic effects are minimal, with benefits contingent on future improvements in patient mortality.
• Pito Chickering (Deutsche Bank) sought details on how changes in commercial mix and ACA enrollment affect revenue per treatment. Ackerman described a sustained negative impact from new patients entering with lower commercial insurance coverage.
• Justin Lake (Wolfe Research) questioned whether recent mortality improvements were driving all volume growth. Ackerman confirmed that improved mortality was the primary factor, with new patient admissions largely unchanged.
• Kevin Fischbeck (Bank of America) inquired about DaVita’s ability to fully deploy expanded HD dialyzers. Rodriguez stated the company has secured sufficient supply to meet physician demand as adoption increases gradually.

Catalysts in Upcoming Quarters

In the upcoming quarters, our analysts will focus on (1) the pace at which expanded HD therapy is adopted across DaVita’s network, (2) updates to Medicare’s ESRD payment rules and their direct financial implications, and (3) whether improvements in patient mortality and volume trends translate into sustained growth. Progress in integrating new clinical technologies and navigating regulatory shifts will be pivotal for DaVita’s performance.

DaVita currently trades at $183.64, down from $227.99 just before the earnings. At this price, is it a buy or sell? See for yourself in our full research report (it’s free).

Our Favorite Stocks Right Now

ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren’t just high-quality businesses. Something is happening with them right now. Elite fundamentals meet near-term momentum — both boxes checked at the same time.

Find out which stocks our AI platform is flagging this week. See this week’s Strong Momentum stocks — FREE. Get Our Strong Momentum Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+271% between June 2020 and June 2025). Find your next big winner with StockStory today.